Few therapies to suppress metastatic disease are known for mCRPC, but GLPG, a rather specific MK5 inhibitor, has recently entered the arena as a metastasis suppressor particularly in a xenograft model of breast cancer. Here, MAPKAPK5 is linked to breast cancer.